# Unraveling the Role of Autotaxin and Lysophosphatidic Acid in Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Potential

## TL;DR

This paper reviews how autotaxin and lysophosphatidic acid may contribute to Alzheimer's disease and could be used as new treatment targets.

## Contribution

The paper provides a synthesis of recent findings on the role of the ATX/LPA axis in Alzheimer's disease.

## Key findings

- ATX and LPA are involved in neuroinflammation and blood–brain barrier dysfunction in Alzheimer's disease.
- LPA signaling affects synaptic plasticity and tau pathology, contributing to AD progression.
- The ATX/LPA axis shows potential as a biomarker and therapeutic target for Alzheimer's disease.

## Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β plaques, tau hyperphosphorylation, and chronic neuroinflammation. Emerging evidence suggests a crucial role of lipid signaling pathways in AD pathogenesis, particularly those mediated by autotaxin (ATX) and lysophosphatidic acid (LPA). ATX, an enzyme responsible for LPA production, has been implicated in neuroinflammatory processes, blood–brain barrier dysfunction, and neuronal degeneration. LPA signaling, through its interaction with specific G-protein-coupled receptors, influences neuroinflammation, synaptic plasticity, and tau pathology, all of which contribute to AD progression. This review synthesizes recent findings on the ATX/LPA axis in AD, exploring its potential as a biomarker and therapeutic target. Understanding the mechanistic links between ATX, LPA, and AD pathology may open new avenues for disease-modifying strategies.